Physician profile
Kathryn E Williams
NPI 1962720862
$7,020.66
in general payments reported to CMS, 2019-2025
36 companies · $752 in 2025
The $752 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $545 · 2021: $569 · 2022: $3,055 · 2023: $635 · 2024: $747 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,133.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,975.01 | 2022-2025 | Inspire |
| Glaxosmithkline, LLC. | $1,088.08 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $508.12 | 2019-2024 | Breztri, Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $394.65 | 2019-2025 | Ofev |
| Harmony Biosciences LLC | $282.72 | 2020-2025 | Wakix |
| Baxter Healthcare | $262.34 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Jazz Pharmaceuticals INC. | $216.85 | 2019-2025 | Xywav |
| Genzyme Corporation | $149.98 | 2022-2025 | |
| Amgen INC. | $110.87 | 2021-2023 | Tezspire |
| Axsome Therapeutics, INC. | $98.84 | 2023-2025 | Sunosi |
| Regeneron Healthcare Solutions, INC. | $82.55 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $82.39 | 2022-2024 | Glassia |
| Philips North America LLC | $77.04 | 2019-2023 | |
| Mylan Specialty L.P. | $75.25 | 2019-2023 | Yupelri |
| Merck Sharp & Dohme LLC | $52.44 | 2019-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $49.87 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $48.39 | 2019 | |
| Electromed, INC. | $44.71 | 2022-2023 | Smartvest |
| Teva Pharmaceuticals USA, INC. | $40.53 | 2020-2021 | |
| Circassia INC. | $39.16 | 2019 | |
| Grifols USA, LLC | $38.41 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $32.73 | 2019 | |
| Insmed, INC. | $30.46 | 2025 | Arikayce |
| Astellas Pharma US INC | $27.26 | 2019-2020 | |
| Avadel Cns Pharmaceuticals, LLC | $26.03 | 2025 | Lumryz |
| Actelion Pharmaceuticals US, INC. | $23.87 | 2022 | |
| United Therapeutics Corporation | $21.10 | 2023 | Tyvaso |
| Advanced Respiratory, INC | $18.54 | 2019 | |
| Phadia US INC. | $18.33 | 2022 | |
| Mallinckrodt Hospital Products INC. | $16.83 | 2022 | |
| Itamar Medical INC | $16.45 | 2024 | Watchpatone |
| 3b Medical, INC. | $15.68 | 2024 | Luna |
| Viatris Specialty LLC | $14.88 | 2025 | Yupelri |
| Fisher & Paykel Healthcare INC | $14.72 | 2024 | Fisher & Paykel Healthcare |
| Inogen, INC. | $13.00 | 2021 | |
| Veran Medical Technologies, INC. | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.